Melinta Therapeutics Lands $67,000,000 New Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fafd2a6c-506a-4750-8fa7-2fad2ad5659c
Date
6/10/2015
Company Name
Melinta Therapeutics
Mailing Address
300 George Street New Haven, CT 06511 USA
Company Description
Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
Website
http://www.melinta.com
Transaction Type
Venture Equity
Transaction Amount
$67,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program.
M&A Terms
Venture Investor
Venture Investor
Venture Investor